What tests are used to diagnose C1 (Complement 1) esterase inhibitor deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Testing for C1 Esterase Inhibitor Deficiency

The diagnosis of C1 esterase inhibitor deficiency requires measurement of complement C4 level as the initial screening test, followed by both C1 inhibitor antigen level and C1 inhibitor functional activity if C4 is low. 1, 2

Initial Screening Test

  • Complement C4 level is the most cost-effective screening test for C1 inhibitor deficiency and should be ordered first in patients with recurrent angioedema without hives. 1, 2

  • At least 95% of patients with C1 inhibitor deficiency will have a reduced C4 level even between attacks, increasing to virtually 100% during acute angioedema episodes. 1

  • A normal C4 level during an attack of angioedema strongly suggests an alternative diagnosis rather than C1 inhibitor deficiency. 1, 3

  • C4 samples must be sent to the laboratory promptly, as degradation can cause artificially low results if there is significant delay in transfer. 1

Confirmatory Testing When C4 is Low

If C4 is low, proceed immediately with:

  • C1 inhibitor antigen (protein) level 1, 2

  • C1 inhibitor functional activity 1, 2

  • The functional level should be less than 50-60% of the lower limit of normal to be compatible with hereditary angioedema. 2, 3

  • Chromogenic functional C1 inhibitor assays are superior to ELISA-based functional assays and should be used preferentially. 2, 4

Interpretation of Results

The pattern of abnormalities distinguishes between types:

  • Type I HAE (85% of cases): Low C4 + low C1 inhibitor antigen + low C1 inhibitor function 2, 3

  • Type II HAE (15% of cases): Low C4 + normal C1 inhibitor antigen + low C1 inhibitor function 2, 3

  • Acquired C1 inhibitor deficiency: Low C4 + low C1 inhibitor antigen/function + low C1q level 2

Additional Testing for Acquired C1 Inhibitor Deficiency

When acquired C1 inhibitor deficiency is suspected based on age of symptom onset (typically >40 years):

  • Measure C1q level to distinguish acquired from hereditary forms 1

  • Consider testing for anti-C1 inhibitor antibodies 1

  • SERPING1 gene sequencing can help distinguish acquired from hereditary deficiency in older patients 1

Quality Control Measures

  • Positive screening test results should be repeated once to exclude ex vivo sample degradation or laboratory error. 2

  • This repeat testing is particularly important for C1 inhibitor function assays, which are susceptible to degradation. 1

Special Populations

  • In pregnancy: Plasma C1 inhibitor levels decrease due to increased plasma volume, so results require cautious interpretation. 2

  • In children: C1 inhibitor and C4 levels reach mature adult levels between 6-36 months and 2-3 years of age respectively, which may affect interpretation in very young children. 2

Critical Pitfall to Avoid

  • C4 levels can be normal if the patient is already receiving treatment for HAE. In such cases, testing should be repeated during an angioedema attack to avoid false-negative screening. 2, 3

  • C1 inhibitor antigenic levels alone cannot be used as the only diagnostic test, as functional testing is essential to identify Type II HAE where antigen levels are normal but function is impaired. 3

When C4 and C1 Inhibitor are Normal

If complement C4 level is normal in a patient with recurrent angioedema, consider HAE with normal C1 inhibitor (HAE-nl-C1INH). 1

  • There is no screening test to rule in this diagnosis—it remains a diagnosis of exclusion. 1

  • Targeted gene sequencing for known HAE pathogenic variants (using next-generation sequencing or Sanger sequencing) should be considered if the patient has a strong family history of angioedema and is unresponsive to mast cell-directed therapy. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis of C1 Esterase Inhibitor Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Hereditary Angioedema

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.